Mizuho reiterates Axsome stock Outperform on Auvelity growth

Auvelity prescriptions rose to 17,162 total and 9,906 new in the week ending March 13, 2026 (+3% and +4% week-over-week), helping drive Axsome's 66% revenue growth over the last 12 months and 93% gross margins. Multiple analysts reiterated or raised price targets (Mizuho $230, UBS $251, RBC $222) and Wolfe initiated coverage at $230, implying substantial upside vs the $156.43 share price (~47%). The company began dosing the first patient in its CLARITY Phase 3 trial for solriamfetol, but shares have seen pressure amid investor concerns about higher sales-force spending.

Analysis

Axsome’s commercial momentum and ongoing pipeline activity create an asymmetric payoff: company-specific catalysts (regulatory decisions and trial readouts) can re-rate the equity independently of the broader biotech tape, while elevated commercial spend amplifies short-term earnings sensitivity. The immediate second-order beneficiaries are commercial infrastructure providers — contract sales firms, field analytics vendors and specialty pharmacies — whose revenues scale with an expanding sales footprint and could see multi-quarter lead indicators of demand before Axsome’s reported numbers move.

Key risks cluster around binary regulatory outcomes and payer/formulary dynamics rather than pure demand: an unfavorable label, restrictive step edits, or a surprise safety signal in an ongoing study would compress valuation multiples quickly, while a clean regulatory outcome should compress implied volatility and push upside higher. Time horizons matter — expect noise over days-weeks around agency and readout windows, fundamental re-rating over 3–12 months tied to formulary placements and durable repeat prescribing, and structural competition impacts over multiple years as alternatives or generics emerge.

Trade implementation should prioritize event-tight sizing and explicit volatility hedges. Because much of the upside is idiosyncratic, neutralize market beta if you want pure company exposure; conversely, asymmetric option structures (long-dated calls or calendar spreads) capture multi-quarter upside while capping near-term downside from commercial burn. Watch liquidity in listed options and dealer skew: implied vols will spike into PDUFA/trial notices and compress on positive outcomes, so timing of entry materially changes IRR.

Key Decisions for Investors

• Initiate a tactical long equity position in AXSM (2% portfolio) into the near-term regulatory window (0–60 days) and immediately hedge with 3-month 10–20% OTM puts to limit downside while retaining upside; goal: asymmetric 2:1 upside/downside if catalyst is positive, stop-loss if put-implied protection cost exceeds 4% of position.
• Buy 9–18 month LEAP calls on AXSM (size 1%–2% portfolio) to capture multi-quarter pipeline and commercialization optionality; reward: multi-bagger on successful readouts/PDUFA, risk: total premium loss if multiple negative outcomes — cap allocation accordingly.
• Event-volatility trade: purchase a 30–60 day straddle or wide strangle ahead of the PDUFA/major trial readout sized to 0.5% portfolio to exploit skew compression on a positive surprise; risk: theta decay, reward: >2x if realized move exceeds implied move priced into options.
• Pair trade to isolate idiosyncratic upside: long AXSM / short IBB (equal dollar) over 3–9 months to hedge biotech-sector beta while keeping company-specific upside; target >1.5x return on positive company news, primary risk is sector rally compressing the spread.